• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012 Product Image

Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

  • ID: 607729
  • November 2008
  • Region: Belgium
  • 80 pages
  • Global Markets Direct

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer HealthCare AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • LifeScan, Inc.
  • Novo Nordisk A/S
  • MORE

Belgium Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the Belgium diabetes care devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the diabetes care devices in Belgium

Scope

- The report provides diabetes care devices information broken down into detailed categories and segments in Belgium.
- Total revenues, products sold, end users, and average pricing.
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions READ MORE >

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer HealthCare AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • LifeScan, Inc.
  • Novo Nordisk A/S
  • MORE

1 2
1.1 List of Tables 6
1.2 List of Figures 8
2 Introduction 9
2.1 What Is This Report About? 9
3 Definitions of the Markets Covered in the Report 10
3.1 Diabetes Care Devices 10
3.2 Glucose Monitoring 10
3.2.1 Blood Glucose Meter 10
3.2.2 Blood Glucose Strips 10
3.3 Insulin Delivery 10
3.3.1 Insulin Pen 10
3.3.2 Insulin Pump 10
3.3.3 Insulin Syringes 11
4 Healthcare Sector Review 12
4.1 Healthcare Expenditure 12
4.2 Healthcare Infrastructure 14
4.2.1 Healthcare Personnel Data 15
4.2.2 Healthcare Facilities Data 16
4.3 Healthcare Policy 17
5 Regulation System 19
5.1 Medical Equipment Approval Process 19
5.1.1 Classification 20
5.1.2 Conformity Assessment Process 29
5.2 Notification Fee 33
6 Pricing and Reimbursement 34
6.1 Reimbursement Policies 34
7 Distribution Structure 35
8 Diabetes Care Devices In Belgium 36
8.1 Diabetes Care Devices Cross Country Comparison (2000-2012) 36
8.2 Diabetes Care Devices, Belgium, Overall Revenues ($ mn), 2000-2012 37
8.3 Diabetes Care Devices, Belgium, Category Volume (Units), 2000-2012 41
8.4 Diabetes Care Devices, Belgium Company share (2006-2007) 44
9 Glucose Monitoring In Belgium 45
9.1 Glucose Monitoring Overall Revenue (2000-2012) 45
9.2 Glucose Monitoring Overall Volume (2000-2012) 47
9.3 Glucose Monitoring Average Price (2000-2012) 49
9.4 Glucose Monitoring Distribution Share (2006-2007) 49
9.5 Glucose Monitoring, Belgium, Company Share (2006-2007) 50
10 Insulin Delivery In Belgium 51
10.1 Insulin Delivery Overall Revenue (2000-2012) 51
10.2 Insulin Delivery Overall Volume (2000-2012) 53
10.3 Insulin Delivery Average Price (2000-2012) 54
10.4 Insulin Delivery Distribution Share (2006-2007) 54
10.5 Insulin Delivery, Belgium, Company Share (2006-2007) 55
11 F. Hoffmann-La Roche Ltd. Company Profile 56
11.1 Company Overview 56
11.2 Value Chain Analysis 56
11.2.1 Manufacturing 57
11.2.2 Product Development 57
11.2.3 Sales and Marketing 58
12 Novo Nordisk A/S Company Profile 59
12.1 Company Overview 59
12.1.1 Novo Nordisk A/S Pipeline Products by Equipment Type 59
12.1.2 Novo Nordisk A/S Pipeline Products by Development Stage 59
12.1.3 Novo Nordisk A/S Pipeline Products by Therapy Area 60
12.1.4 Novo Nordisk A/S Pipeline Products by Clinical Trials 60
13 LifeScan, Inc. Company Profile 61
13.1 Company Overview 61
13.1.1 LifeScan, Inc. Pipeline Products by Equipment Type 61
13.1.2 LifeScan, Inc. Pipeline Products by Development Stage 61
13.1.3 LifeScan, Inc. Pipeline Products by Therapy Area 61
13.1.4 LifeScan, Inc. Pipeline Products by Clinical Trials 62
13.1.5 LifeScan, Inc. Pipeline Products by News Summary 62
14 Abbott Laboratories Company Profile 63
14.1 Company Overview 63
14.2 Value Chain Analysis 63
14.2.1 Manufacturing 64
14.2.2 Product Development 64
14.2.3 Sales and Marketing 65
14.2.4 Abbott Laboratories Pipeline Products by Equipment Type 65
14.2.5 Abbott Laboratories Pipeline Products by Development Stage 66
14.2.6 Abbott Laboratories Pipeline Products by Therapy Area 66
14.2.7 Abbott Laboratories Pipeline Products by Clinical Trials 66
14.2.8 Abbott Laboratories Pipeline Products by News Summary 66
15 Bayer HealthCare AG Company Profile 67
15.1 Company Overview 67
15.2 Value Chain Analysis 67
15.2.1 Manufacturing 68
15.2.2 Product Development 68
15.2.3 Sales and Marketing 69
15.3 Bayer HealthCare AG Pipeline Products 69
15.3.1 Bayer HealthCare AG Pipeline Products by Equipment Type 69
15.3.2 Bayer HealthCare AG Pipeline Products by Development Stage 70
15.3.3 Bayer HealthCare AG Pipeline Products by Therapy Area 70
15.3.4 Bayer HealthCare AG Pipeline Products by News Summary 70
16 Eli Lilly and Company Company Profile 71
16.1 Company Overview 71
16.2 Value Chain Analysis 71
16.2.1 Manufacturing 72
16.2.2 Product Development 72
16.2.3 Sales and Marketing 73
16.2.4 Eli Lilly and Company Pipeline Products by Equipment Type 73
16.2.5 Eli Lilly and Company Pipeline Products by Development Stage 74
16.2.6 Eli Lilly and Company Pipeline Products by Therapy Area 74
17 Appendix 75
17.1 Global Markets Direct Research Methodology 75
17.2 Coverage 76
17.3 Secondary Research 76
17.4 Primary Research 77
17.5 Models 77
17.6 Forecasts 78
17.7 Expert Panels 78
17.8 Currency Conversion 79
17.9 Contact Us 80
17.10 Disclaimer 80

Executive Summary

1.2 List of Figures
Figure 1: Total Healthcare Expenditure in Belgium, 2000 - 2006 13
Figure 2: Structure of Healthcare System in Belgium, 2007 18
Figure 3: Flowchart for Classification of Non-invasive Devices in Belgium, 2007 21
Figure 4: Flowchart for Classification of Invasive Devices in Belgium, 2007 22
Figure 5: Flowchart for Classification of Invasive Devices in Belgium, 2007 23
Figure 6: Flowchart for Classification of Invasive Devices in Belgium, 2007 24
Figure 7: Flowchart for Classification of Invasive Devices in Belgium, 2007 25
Figure 8: Flowchart for Classification of Active Devices in Belgium, 2007 26
Figure 9: Flowchart for Classification of Active Devices in Belgium, 2007 27
Figure 10: Flowchart for Classification of Devices except Non-invasive, Invasive and Active Devices in Belgium, 2007 28
Figure 11: Conformity Assessment of Class-I Medical Devices in Belgium, 2007 29
Figure 12: Conformity Assessment of Class-IIa Medical Devices in Belgium, 2007 30
Figure 13: Conformity Assessment of Class-IIb Medical Devices in Belgium, 2007 31
Figure 14: Conformity Assessment of Class-III Medical Devices in Belgium, 2007 32
Figure 15: Diabetes Care Devices Cross Country Comparison (2000-2012) 36
Figure 16: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), 2000-2012 37
Figure 17: Diabetes Care Devices, Belgium, Portfolio Analysis, 2000-2012 38
Figure 18: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), Historic, 2000-2007 39
Figure 19: Diabetes Care Devices, Belgium, Overall Revenues ($ mn), Forecast, 2007-2012 40
Figure 20: Diabetes Care Devices, Belgium, Category Volume (Units), 2000-2012 41
Figure 21: Diabetes Care Devices, Belgium, Category Volume (Units), Historic, 2000-2007 42
Figure 22: Diabetes Care Devices, Belgium, Category Volume (Units), Forecast, 2007-2012 43
Figure 23: Diabetes Care Devices, Belgium Company share (%), 2007 44
Figure 24: Glucose Monitoring, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 45
Figure 25: Glucose Monitoring, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 46
Figure 26: Glucose Monitoring, Belgium, Overall Volume (Units), Historic, 2000-2007 47
Figure 27: Glucose Monitoring, Belgium, Overall Volume (Units), Forecast, 2007-2012 48
Figure 28: Glucose Monitoring, Belgium, Company Share (%), 2007 50
Figure 29: Insulin Delivery, Belgium, Revenue ($ mn) by Segment, Historic, 2000-2007 51
Figure 30: Insulin Delivery, Belgium, Revenue ($ mn) by Segment, Forecast, 2007-2012 52
Figure 31: Insulin Delivery, Belgium, Company Share (%), 2007 55
Figure 32: F. Hoffmann-La Roche Ltd Value Chain Analysis 56
Figure 33: Abbott Laboratories Value Chain Analysis 63
Figure 34: Bayer HealthCare AG Value Chain Analysis 67
Figure 35: Eli Lilly and Company Value Chain Analysis 71
Figure 36: Global Markets Direct Methodology 75

Note: Product cover images may vary from those shown

F. Hoffmann-La Roche Ltd.
Novo Nordisk A/S
LifeScan, Inc.
Abbott Laboratories
Bayer HealthCare AG
Eli Lilly and Company

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos